Chief Medical Officer | Executive Vice President - Clinical and Medical Affairs
Non-Invasive, Transformational Approach to Treating Retinal Disease.OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity